Advertisement
Document › Details
Merck KGaA. (8/6/19). "Press Release: Merck Acquires BSSN Software to Accelerate Customers’ Digital Transformation in the Lab". Darmstadt.
Organisation | Merck KGaA | |
Group | Merck (DE) (Group) | |
Organisation 2 | BSSN Software GmbH | |
Group | Merck (DE) (Group) | |
Product | LIMS (laboratory information management system) | |
Product 2 | software | |
Person | Wirth, Jean-Charles (Merck (DE) 201708 Head of Applied Solutions business unit, Life Science) | |
Person 2 | Tiano, Karen Spiller (Merck (DE) 201903) | |
> Gives scientists better, more efficient access to their lab data
> Boosts Merck’s digital laboratory productivity business, commercial growth
Merck, a leading science and technology company, has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and long-term archiving. Financial details were not disclosed.
“BSSN Software and the capabilities that it brings will allow Merck’s customers to better use and share their scientific data — the most important part of laboratory experiments,” said Jean-Charles Wirth, head of Applied Solutions at the Life Science business sector of Merck. “We acquired this company for commercial growth of the lab data management technology that BSSN provided for many years. This acquisition creates opportunity and gives Merck a unique position in this fast-paced market.”
BSSN Software is known for developing and marketing data management and integration software that unifies data from instruments and data systems and makes them available for analyzing, processing and sharing. It collects and converts scientific data from a broad range of more than 200 lab instrument models into a single, unified format. As a middleware offering, it facilitates communication and data flow between instruments and systems, such as laboratory information management systems, electronic lab notebooks and enterprise resource planning systems. The acquisition complements Merck’s efforts to support its customers’ digital transformation in the lab.
Since 2014, Merck has been working with BSSN Software, which primarily served pharmaceutical and food and beverage customers and provided services to facilitate standard laboratory efforts. BSSN Software was the first company to introduce to the market a complete AnIML implementation, an open standardized XML data format for storing and sharing of experiment data. With this acquisition, Merck is combining BSSN’s technology with its market access and laboratory domain knowledge to develop and commercialize an open and interoperable platform for laboratory data.
Merck is committed to the continued development and support of the current BSSN Software product portfolio, its customers and partnerships, as well as an open ecosystem building on the AnIML standard and Standardization in Lab Automation.
BSSN’s employees have joined Merck as part of its Applied Digital Lab Productivity Solutions team.
For more information, please contact
Karen Tiano
+49 6151 72 44461
Follow Merck on Twitter @Merckgroup, on Facebook @merckgroup and on LinkedIn.
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene- editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2018, Merck generated sales of €14.8 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the business sectors operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
Record changed: 2023-06-05 |
Advertisement
More documents for Merck (DE) (Group)
- [1] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
- [2] BioGeneration Ventures B.V.. (4/2/24). "Press Release: BGV Appoints Peter Halle, PhD as Venture Partner". Amsterdam....
- [3] C4 Therapeutics, Inc.. (3/4/24). "Press Release: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins". Watertown, MA....
- [4] Precirix N.V.. (2/29/24). "Press Release: Tom Plitz Commences Role as Chief Executive Officer of Precirix". Brussels....
- [5] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [6] ITM Isotope Technologies Munich SE. (12/14/23). "Press Release: ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics". Garching....
- [7] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [8] Merck KGaA. (11/21/23). "Press Release: Merck Expands Newest Biologics Testing Center in Shanghai". Shanghai....
- [9] Merck KGaA. (11/14/23). "Press Release: Merck Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District [Not intended for US-based media]". Darmstadt....
- [10] Merck KGaA. (10/30/23). "Press Release: Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate [Not intended for US-, Canada- or UK-based media]". Darmstadt...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top